The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) — A Fundamental Ally in AD Prevention Research - 21/11/24
Conflict of interests: Dr. Porsteinsson reports personal fees from Acadia Pharmaceuticals, Avanir, Cadent Therapeutics, Eisai, Functional Neuromodulation, and Tetra Discovery Partners; grants to his institution from Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, Novartis, outside of the submitted work. Dr. Clark has nothing to disclose. |
Vol 7 - N° 4
P. 206-207 - Settembre 2020 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.